Li Sujuan, Tian Anran, Wen Yu, Gu Wei, Li Wei, Qiao Xiaohong, Zhang Cai, Luo Xiaoping
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Department of Pediatrics, The First People's Hospital of Urumqi, Urumqi, 830000, People's Republic of China.
Eur J Pediatr. 2024 May;183(5):2257-2272. doi: 10.1007/s00431-024-05484-9. Epub 2024 Feb 27.
Patients with Aarskog-Scott syndrome (AAS) have short stature, facial anomalies, skeletal deformities, and genitourinary malformations. FYVE, RhoGEF, and PH domain-containing 1 (FGD1) is the only known causative gene of AAS. However, the diagnosis of AAS remains difficult, and specific treatments are still absent. Patients suspected with AAS were recruited, and clinical information was collected. Genetic testing and functional analysis were carried out for the diagnosis. By literature review, we summarized the clinical and genetic characteristics of FGD1-related AAS and analyzed the genotype-phenotype correlation. Five patients were recruited, and four novel FGD1 variants were identified. The diagnosis of AAS was confirmed by genetic analysis and functional study. Three patients treated with growth hormone showed improved heights during the follow-up period. By literature review, clinical features of AAS patients with FGD1 variants were summarized. Regarding FGD1 variations, substitutions were the most common form, and among them, missense variants were the most frequent. Moreover, we found patients with drastic variants showed higher incidences of foot and genitourinary malformations. Missense variants in DH domain were related to a lower incidence of cryptorchidism. Conclusion: We reported four novel pathogenic FGD1 variations in AAS patients and confirmed the efficacy and safety of growth hormone treatment in FGD1-related AAS patients with growth hormone deficiency. Additionally, our literature review suggested the crucial role of DH domain in FGD1 function. What is Known: • Aarskog-Scott syndrome is a rare genetic disease, and the only known cause is the variant in FGD1 gene. The typical clinical manifestations of AAS include facial, skeletal, and urogenital deformities and short stature. What is New: • We reported four novel FGD1 variants and reported the treatment of growth hormone in FGD1-related AAS patients. Our genotype-phenotype correlation analysis suggested the crucial role of DH domain in FGD1 function.
患有阿斯克格-斯科特综合征(AAS)的患者身材矮小、面部异常、骨骼畸形以及泌尿生殖系统畸形。含FYVE、RhoGEF和PH结构域蛋白1(FGD1)是已知的唯一导致AAS的致病基因。然而,AAS的诊断仍然困难,且尚无特效治疗方法。招募了疑似患有AAS的患者并收集了临床信息。进行了基因检测和功能分析以明确诊断。通过文献综述,我们总结了FGD1相关AAS的临床和遗传特征,并分析了基因型与表型的相关性。招募了5名患者,鉴定出4种新的FGD1变异体。通过基因分析和功能研究确诊为AAS。3名接受生长激素治疗的患者在随访期间身高有所改善。通过文献综述,总结了具有FGD1变异体的AAS患者的临床特征。关于FGD1变异,替换是最常见的形式,其中错义变异最为频繁。此外,我们发现具有严重变异的患者足部和泌尿生殖系统畸形的发生率更高。DH结构域中的错义变异与隐睾症的发生率较低有关。结论:我们报告了AAS患者中4种新的致病性FGD1变异,并证实了生长激素治疗对生长激素缺乏的FGD1相关AAS患者的有效性和安全性。此外,我们的文献综述表明DH结构域在FGD1功能中起关键作用。已知信息:• 阿斯克格-斯科特综合征是一种罕见的遗传性疾病,唯一已知病因是FGD1基因变异。AAS的典型临床表现包括面部、骨骼和泌尿生殖系统畸形以及身材矮小。新发现:• 我们报告了4种新的FGD1变异,并报告了生长激素对FGD1相关AAS患者的治疗情况。我们的基因型-表型相关性分析表明DH结构域在FGD1功能中起关键作用。